For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.
Price · 1Y
$46.54
Thesis
CRISPR Therapeutics commercialized one of the first approved CRISPR-based medicines and is extending editing into in vivo and immuno-oncology programs. An approved therapy plus a deep pipeline anchors a leading position in gene editing.
Catalysts
- Casgevy commercial ramp and patient starts
- In vivo editing program readouts
- Cell-therapy and cardiovascular pipeline progress
Recent events
Material filings, federal awards, and regulatory activity. Impact is scored against market cap.
- Jul 23Trial initiationClinicalTrials.gov
CRISPR Therapeutics initiates Phase 1 safety trial of CTX310 for refractory dyslipidemias (NCT07491172).
- Jul 22Trial initiationClinicalTrials.gov
CRISPR Therapeutics initiates Phase 1/2 trial (NCT07549698) of CTX112 in relapsed/refractory hematologic autoimmune disease; status recruiting.
- Jul 20Trial initiationClinicalTrials.gov
CRISPR Therapeutics initiates Phase 1 safety trial NCT07491172 of CTX310 in refractory dyslipidemias (status: recruiting).
- Jul 16Trial initiationClinicalTrials.gov
CRISPR Therapeutics begins Phase 1/2 trial (NCT07549698) of CTX112 in relapsed/refractory hematologic autoimmune disease; status recruiting.
- Jun 15Trial initiationClinicalTrials.gov
CRISPR Therapeutics initiates Phase 1/2 trial (NCT07549698) of CTX112 in relapsed/refractory hematologic autoimmune disease; status recruiting.
- Jun 4LeadershipSEC
8-K reports items 5.02/5.03/5.07: officer/director changes, bylaw amendments, and shareholder vote results.
- May 22Trial initiationClinicalTrials.gov
CRISPR Therapeutics initiates Phase 1 safety trial of CTX310 in refractory dyslipidemias (NCT07491172, recruiting)
- May 7Trial readoutClinicalTrials.gov
CRISPR terminates Phase 1 FIH trial NCT05565248 of VCTX211 in T1D (status updated 2026-05-07)